Absence of Iodinated Contrast Hypersensitivity and Characterization of Gadolinium Utilization in an Interventional Pain Population.
contrast allergy
epidural
epidural analgesia
gadolinium
Journal
Pain practice : the official journal of World Institute of Pain
ISSN: 1533-2500
Titre abrégé: Pain Pract
Pays: United States
ID NLM: 101130835
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
14
07
2020
revised:
10
08
2020
accepted:
28
08
2020
pubmed:
9
9
2020
medline:
20
7
2021
entrez:
8
9
2020
Statut:
ppublish
Résumé
Iodinated contrast media (ICM) allergy labels pose a unique clinical problem for the interventional pain physician due to the drawbacks of gadolinium for enhancement during pain procedures, as well as the reluctance to add to the cumulative steroid burden with steroid premedication. However, the risks of ICM hypersensitivity specific to this setting have not been previously described. We aimed to describe the incidence of ICM-induced hypersensitivity during the performance of epidural injections in a large healthcare system. We also sought to characterize preexisting ICM allergy labels and how these affected consequent gadolinium utilizations in this population. 6,471 epidural pain procedures requiring contrast enhancement were performed during the 18-month study period. There were no reported contrast-induced hypersensitivity reactions in this time. 108 patients (1.6%) had a preexisting ICM allergy; a shellfish/seafood allergy was recorded in 118 patients (1.82%), and 51 charts (0.78%) were labeled with "iodine" allergy. 183 individuals received gadolinium for enhancement during epidural steroid injections. 96.7% of gadolinium utilization occurred in the context of preexisting allergy labels in the electronic medical record. Of note, 20 patients (18.5%) with ICM allergy labels also received iodinated contrast, and this was uneventful in all cases. Our results suggest that ICM-associated hypersensitivity is very rare during epidural procedures and the incidence is significantly lower than expected based on reaction rates during intravascular administration. This may be related to both dose as well as route of administration. The establishment of a protocol for safe workup of ICM allergy labels would be useful in optimizing pain procedures.
Sections du résumé
BACKGROUND
Iodinated contrast media (ICM) allergy labels pose a unique clinical problem for the interventional pain physician due to the drawbacks of gadolinium for enhancement during pain procedures, as well as the reluctance to add to the cumulative steroid burden with steroid premedication. However, the risks of ICM hypersensitivity specific to this setting have not been previously described.
METHODS
We aimed to describe the incidence of ICM-induced hypersensitivity during the performance of epidural injections in a large healthcare system. We also sought to characterize preexisting ICM allergy labels and how these affected consequent gadolinium utilizations in this population.
RESULTS
6,471 epidural pain procedures requiring contrast enhancement were performed during the 18-month study period. There were no reported contrast-induced hypersensitivity reactions in this time. 108 patients (1.6%) had a preexisting ICM allergy; a shellfish/seafood allergy was recorded in 118 patients (1.82%), and 51 charts (0.78%) were labeled with "iodine" allergy. 183 individuals received gadolinium for enhancement during epidural steroid injections. 96.7% of gadolinium utilization occurred in the context of preexisting allergy labels in the electronic medical record. Of note, 20 patients (18.5%) with ICM allergy labels also received iodinated contrast, and this was uneventful in all cases.
CONCLUSION
Our results suggest that ICM-associated hypersensitivity is very rare during epidural procedures and the incidence is significantly lower than expected based on reaction rates during intravascular administration. This may be related to both dose as well as route of administration. The establishment of a protocol for safe workup of ICM allergy labels would be useful in optimizing pain procedures.
Substances chimiques
Contrast Media
0
Iodine
9679TC07X4
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
184-189Informations de copyright
© 2020 World Institute of Pain.
Références
Macy EM. Current epidemiology and management of radiocontrast-associated acute- and delayed-onset hypersensitivity: a review of the literature. Perm J. 2018;22:17-072.
Li X, Liu H, Zhao L, et al. Clinical observation of adverse drug reactions to non-ionic iodinated contrast media in population with underlying diseases and risk factors. Br J Radiol. 2017;90:20160729.
Mishra RK, Heavner JE, Day M. Prevalence of adverse reactions to radiopaque contrast reported by patients presenting for interventional pain procedure. Pain Pract. 2013;13:182-190.
Davis PL. Anaphylactoid reactions to the nonvascular administration of water-soluble iodinated contrast media. Am J Roentgenol. 2015;204:1140-1145.
Moses RA, Vollstedt AJ, Pais VM Jr. "Allergic-like" reaction risk in patients undergoing non-intravenous contrast urography. Can J Urol. 2018;25:9601-9605.
Benzon HT, Schechtman J, Zheng SC, et al. Patients with a history of hypersensitivity reaction to iodinated contrast medium and given iodinated contrast during an interventional pain procedure. Reg Anesth Pain Med. 2019;44:118-121.
Macy E, Ho NJ. Multiple drug intolerance syndrome: prevalence, clinical characteristics, and management. Ann Allergy Asthma Immunol. 2012;108:88-93.
Abe S, Fukuda H, Tobe K, Ibukuro K. Protective effect against repeat adverse reactions to iodinated contrast medium: premedication vs. changing the contrast medium. Eur Radiol. 2016;26:2148-2154.
Hooten WM, Nicholson WT, Gazelka HM, Reid JM, Moeschler SM, Lamer TJ. Serum triamcinolone levels following interlaminar epidural injection. Reg Anesth Pain Med. 2016;41:75-79.
Lamer TJ, Dickson RR, Gazelka HM, et al. Serum triamcinolone levels following cervical interlaminar epidural injection. Pain Res Manag. 2018;2018:8474127.
Davenport MS, Cohan RH. The evidence for and against corticosteroid prophylaxis in at-risk patients. Radiol Clin North Am. 2017;55:413-421.
Sanchez-Borges M, Aberer W, Brockow K, et al. Controversies in drug allergy: radiographic contrast media. J Allergy Clin Immunol Pract. 2019;7:61-65.
Maus TP, Schueler BA, Magnuson DJ, Magnuson D. Relative conspicuity of gadolinium-based contrast agents in interventional pain procedures. Pain Med. 2017;18:651-654.
Safriel Y, Ang R, Ali M. Gadolinium use in spine pain management procedures for patients with contrast allergies: results in 527 procedures. Cardiovasc Intervent Radiol. 2008;31:325-331.
Popescu A, Patel J, Smith CC, Patient Safety Committee of the Spine Intervention Society. Are gadolinium-based contrast media safe alternatives for spine procedures? Pain Med. 2017;18:2248-2249.
Renaudin JM, Beaudouin E, Ponvert C, Demoly P, Moneret-Vautrin DA. Severe drug-induced anaphylaxis: analysis of 333 cases recorded by the Allergy Vigilance Network from 2002 to 2010. Allergy 2013;68:929-937.
Scheinfeld MH, Sprayregen S, Jerschow E, Dym RJ. Contrast is the new penicillin, and possibly worse. J Am Coll Radiol. 2015;12:942-943.
Cochran ST, Bomyea K. Trends in adverse events from iodinated contrast media. Acad Radiol. 2002;9(suppl 1):S65-S68.
Gomi T, Nagamoto M, Hasegawa M, et al. Are there any differences in acute adverse reactions among five low-osmolar non-ionic iodinated contrast media? Eur Radiol. 2010;20:1631-1635.